433 related articles for article (PubMed ID: 33526482)
1. Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2.
Kuo CJ; Chao TL; Kao HC; Tsai YM; Liu YK; Wang LH; Hsieh MC; Chang SY; Liang PH
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526482
[TBL] [Abstract][Full Text] [Related]
2. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
3. Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library.
Lee JY; Kuo CJ; Shin JS; Jung E; Liang PH; Jung YS
Bioorg Med Chem Lett; 2021 Jun; 42():128067. PubMed ID: 33957246
[TBL] [Abstract][Full Text] [Related]
4. Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing.
Pathak N; Chen YT; Hsu YC; Hsu NY; Kuo CJ; Tsai HP; Kang JJ; Huang CH; Chang SY; Chang YH; Liang PH; Yang JM
ACS Nano; 2021 Jan; 15(1):857-872. PubMed ID: 33373194
[TBL] [Abstract][Full Text] [Related]
5. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL
Jade D; Ayyamperumal S; Tallapaneni V; Joghee Nanjan CM; Barge S; Mohan S; Nanjan MJ
Eur J Pharmacol; 2021 Jun; 901():174082. PubMed ID: 33823185
[TBL] [Abstract][Full Text] [Related]
6. A Patent Review on SARS Coronavirus Papain-Like Protease (PL
Brian Chia CS; Pheng Lim S
ChemMedChem; 2023 Aug; 18(16):e202300216. PubMed ID: 37248169
[TBL] [Abstract][Full Text] [Related]
7. Structure-Based Identification of Naphthoquinones and Derivatives as Novel Inhibitors of Main Protease M
Santos LH; Kronenberger T; Almeida RG; Silva EB; Rocha REO; Oliveira JC; Barreto LV; Skinner D; Fajtová P; Giardini MA; Woodworth B; Bardine C; Lourenço AL; Craik CS; Poso A; Podust LM; McKerrow JH; Siqueira-Neto JL; O'Donoghue AJ; da Silva Júnior EN; Ferreira RS
J Chem Inf Model; 2022 Dec; 62(24):6553-6573. PubMed ID: 35960688
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.
Hoffman RL; Kania RS; Brothers MA; Davies JF; Ferre RA; Gajiwala KS; He M; Hogan RJ; Kozminski K; Li LY; Lockner JW; Lou J; Marra MT; Mitchell LJ; Murray BW; Nieman JA; Noell S; Planken SP; Rowe T; Ryan K; Smith GJ; Solowiej JE; Steppan CM; Taggart B
J Med Chem; 2020 Nov; 63(21):12725-12747. PubMed ID: 33054210
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture.
Bafna K; White K; Harish B; Rosales R; Ramelot TA; Acton TB; Moreno E; Kehrer T; Miorin L; Royer CA; García-Sastre A; Krug RM; Montelione GT
Cell Rep; 2021 May; 35(7):109133. PubMed ID: 33984267
[TBL] [Abstract][Full Text] [Related]
10. Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization.
Di Sarno V; Lauro G; Musella S; Ciaglia T; Vestuto V; Sala M; Scala MC; Smaldone G; Di Matteo F; Novi S; Tecce MF; Moltedo O; Bifulco G; Campiglia P; Gomez-Monterrey IM; Snoeck R; Andrei G; Ostacolo C; Bertamino A
Eur J Med Chem; 2021 Dec; 226():113863. PubMed ID: 34571172
[TBL] [Abstract][Full Text] [Related]
11. Novel dithiocarbamates selectively inhibit 3CL protease of SARS-CoV-2 and other coronaviruses.
Brier L; Hassan H; Hanoulle X; Landry V; Moschidi D; Desmarets L; Rouillé Y; Dumont J; Herledan A; Warenghem S; Piveteau C; Carré P; Ikherbane S; Cantrelle FX; Dupré E; Dubuisson J; Belouzard S; Leroux F; Deprez B; Charton J
Eur J Med Chem; 2023 Mar; 250():115186. PubMed ID: 36796300
[TBL] [Abstract][Full Text] [Related]
12. Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CL
Ma L; Xie Y; Zhu M; Yi D; Zhao J; Guo S; Zhang Y; Wang J; Li Q; Wang Y; Cen S
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555652
[TBL] [Abstract][Full Text] [Related]
13.
Liu H; Ye F; Sun Q; Liang H; Li C; Li S; Lu R; Huang B; Tan W; Lai L
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):497-503. PubMed ID: 33491508
[TBL] [Abstract][Full Text] [Related]
14.
Tronco Pauletto PJ; Omage FB; Delgado CP; Nogara PA; Teixeira Rocha JB
Curr Drug Discov Technol; 2023; 20(2):e101022209771. PubMed ID: 36221883
[TBL] [Abstract][Full Text] [Related]
15. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA
J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315
[TBL] [Abstract][Full Text] [Related]
16. Production of a functionally active recombinant SARS-CoV-2 (COVID-19) 3C-like protease and a soluble inactive 3C-like protease-RBD chimeric in a prokaryotic expression system.
De Marco Verissimo C; López Corrales J; Dorey AL; Cwiklinski K; Lalor R; Calvani NED; Jewhurst HL; Flaus A; Doyle S; Dalton JP
Epidemiol Infect; 2022 Jun; 150():e128. PubMed ID: 35723031
[TBL] [Abstract][Full Text] [Related]
17. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL
Ma L; Li Q; Xie Y; Jianyuan Zhao ; Yi D; Guo S; Guo F; Wang J; Yang L; Cen S
Antiviral Res; 2022 Nov; 207():105419. PubMed ID: 36155070
[TBL] [Abstract][Full Text] [Related]
18. Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV).
Dampalla CS; Miller MJ; Kim Y; Zabiegala A; Nguyen HN; Madden TK; Thurman HA; Machen AJ; Cooper A; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC
Eur J Med Chem; 2023 Jun; 254():115376. PubMed ID: 37080108
[TBL] [Abstract][Full Text] [Related]
19. Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors.
Osipiuk J; Azizi SA; Dvorkin S; Endres M; Jedrzejczak R; Jones KA; Kang S; Kathayat RS; Kim Y; Lisnyak VG; Maki SL; Nicolaescu V; Taylor CA; Tesar C; Zhang YA; Zhou Z; Randall G; Michalska K; Snyder SA; Dickinson BC; Joachimiak A
Nat Commun; 2021 Feb; 12(1):743. PubMed ID: 33531496
[TBL] [Abstract][Full Text] [Related]
20. Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors.
Ghosh AK; Shahabi D; Yadav M; Kovela S; Anson BJ; Lendy EK; Bonham C; Sirohi D; Brito-Sierra CA; Hattori SI; Kuhn R; Mitsuya H; Mesecar AD
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
